Propelled by DiaMed Acquisition, Bio-Rad's Q3 Revenues Climb 30 Percent | GenomeWeb
This article has been updated with analysts' EPS estimate and a stock quote.
 
NEW YORK (GenomeWeb News) - Bio-Rad Laboratories today reported a 30 percent increase in third-quarter revenues, driven by its acquisition last year of DiaMed Holdings, but charges related to the acquisition cut into the firm’s profit for the quarter.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.